var data={"title":"Oxacillin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxacillin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6691?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxacillin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxacillin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxacillin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452679\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bactocill in Dextrose</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204217\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204193\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> May contain a significant amount of sodium; consult product specific labeling for amount.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Catheter-related bloodstream infections (off-label use):</b> IV: 2 g every 4 hours (Mermel 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment: Methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA) (off-label dose; AHA [Baddour 2015]):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Native valve: 12 g/day in 4 or 6 divided doses (ie, 2 g every 4 hours or 3 g every 6 hours) for 6 weeks.<b> Note:</b> Dosing intended for <b><i>complicated</i></b> right-sided infective endocarditis (IE) or left-sided IE. For <b><i>uncomplicated</i></b> right-sided IE, 2 weeks of therapy may be adequate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prosthetic valve: 12 g/day in 6 divided doses (ie, 2 g every 4 hours) for at least 6 weeks (use with rifampin for entire course and gentamicin for first 2 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mild to moderate infections:</b> IM, IV: 250 to 500 mg every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis, native vertebral (off-label dose): </b>\n      <i>Staphylococcus </i>(oxacillin-susceptible): IV: 1.5 to 2 g every 4 to 6 hours or via continuous infusion for 6 weeks (IDSA [Berbari 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection:</b> IV: 2 g every 4 hours with rifampin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe infections:</b> IM, IV: 1 g every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Staphylococcus aureus, </i></b> <b>methicillin-susceptible infections, including brain abscess, bursitis, erysipelas, mastitis, mastoiditis, osteomyelitis, perinephric abscess, pneumonia, pyomyositis, scalded skin syndrome, toxic shock syndrome:</b> IV: 2 g every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections (IDSA [Stevens 2014]):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Due to methicillin-susceptible Staphylococcus aureus (MSSA):</i> 1 to 2 g every 4 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Necrotizing infection due to MSSA (off-label use):</i> 1 to 2 g every 4 hours; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical site infections (trunk or extremity [away from axilla or perineum]) (off-label use):</b> IV: 2 g every 6 hours (IDSA [Stevens 2014])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204208\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxacillin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> May contain a significant amount of sodium; consult product specific labeling for amount.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate infections:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;40 kg: IM, IV: 50 mg/kg/day in divided doses every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;40 kg and Adolescents: IM, IV: 250 to 500 mg every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing</i>: Infants, Children, and Adolescents: IM, IV: 100 to 150 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4,000 mg/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe infections:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;40 kg: IM, IV: 100 mg/kg/day in divided doses every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;40 kg and Adolescents: IM, IV: 1,000 mg every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing</i>: Infants, Children, and Adolescents: IM, IV: 150 to 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g/day</b> (<i>Red Book</i> [AAP 2015]); however, manufacturer labeling suggests a maximum daily dose of 6 <b>g/day</b> in adults when treating severe infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Catheter-related bloodstream infections:</b> Infants and Children: IV: 150 to 200 mg/kg/day divided every 4 to 6 hours (Mermel 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Community-acquired pneumonia (CAP), moderate to severe infection, <i>S. aureus</i> (methicillin-susceptible) (preferred):</b> Infants &gt;3 months, Children and Adolescents: IV: 150 to 200 mg/kg/day divided every 6 to 8 hours (IDSA/PIDS [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (off-label)</b>: Children and Adolescents: IV: 200 mg/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 <b>g/day</b>; treat for at least 4 weeks; longer duration may be necessary; may use in combination with gentamicin for some resistant organisms (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis:</b> Infants, Children, and Adolescents: IV: 200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 <b>g/day</b> (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infections (IDSA [Stevens 2014]):</b> Infants, Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Due to methicillin-susceptible Staphylococcus aureus (MSSA):</i> IV: 100 to 150 mg/kg/day in divided doses every 6 hours for 7 to 14 days; maximum daily dose: 12 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Necrotizing infection due to MSSA (off-label use):</i> IV: 200 mg/kg/day in divided doses every 6 hours; continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours. Maximum daily dose: 12 <b>g/day</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204194\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. <b>Note:</b> May contain a significant amount of sodium; consult product specific labeling for amount. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important in diseases such as congestive heart failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204195\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, manufacturer suggests considering a reduction in total dosage if renal impairment is known or suspected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548161\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204167\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bactocill in Dextrose: 1 g/50 mL (50 mL); 2 g/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204151\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204171\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer IVP over 10 minutes or IVPB over 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204170\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Staphylococcal infections:</b> Treatment of infections caused by penicillinase-producing staphylococci that have demonstrated susceptibility to the drug; empiric therapy in suspected cases of resistant staphylococcal infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Limitations of use: Oxacillin should not be used in infections caused by organisms susceptible to penicillin G.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26191114\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Catheter-related bloodstream infections; Community-acquired pneumonia (children); Skin and soft tissue necrotizing infections; Surgical site infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204158\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, eosinophilia, leukopenia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Serum sickness-like reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute interstitial nephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204174\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis) to oxacillin, any penicillin, or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204155\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in patients with histories of significant allergies and/or asthma; discontinue treatment and institute appropriate therapy if an allergic reaction occurs</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatitis: Acute hepatitis and reversible elevations of serum transaminases have been reported sometimes accompanied by rash and leukopenia; onset after 2 to 3 weeks of therapy; monitor periodically throughout therapy (Dahlgren 1997; Faden 2009; Maraqa 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: May contain a significant amount of sodium; consult product specific labeling for amount. The elderly population may respond with a blunted natriuresis to salt loading. This may be clinically important in diseases such as congestive heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neonates: Use with caution in neonates; elimination of drug is decreased; dosage adjustment is needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299797\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204160\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9724&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204176\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Oxacillin is distributed into the amniotic fluid and is detected in cord blood. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204177\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Oxacillin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering oxacillin to nursing women. Nondose-related effects could include modification of bowel flora. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204178\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204165\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for signs and symptoms of anaphylaxis during first dose; monitor periodic CBC, urinalysis, BUN, serum creatinine, AST and ALT</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204154\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204173\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Into bile, amniotic, and pleural fluids; insignificant concentrations in CSF and aqueous humor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~94% (mainly albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates (PNA: 8 to 15 days): 1.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children &le;2 years: 0.9 to 1.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 20 to 30 minutes; prolonged with renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 30 minutes; IV: 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and bile (unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323563\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bactocill in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $17.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 gm/50 mL (50 mL): $24.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Oxacillin Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $17.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $33.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $138.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038712\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Biotam (VN);</li>\n      <li>Bristopen (FR);</li>\n      <li>Cloxacap (SG);</li>\n      <li>Cloxcin (SG);</li>\n      <li>Minzil (PH);</li>\n      <li>Ocillina (TW);</li>\n      <li>Ocina (VN);</li>\n      <li>Oxacilina (CO);</li>\n      <li>Oxacillin (PL);</li>\n      <li>Oxan (PH);</li>\n      <li>Oxanon (BR);</li>\n      <li>Oxapen (PH);</li>\n      <li>Oxatalis (PH);</li>\n      <li>Penstapho (BE, IT);</li>\n      <li>Procillin (KR);</li>\n      <li>Prostafilina (VE);</li>\n      <li>Prostaphlin (CZ, EE, HN);</li>\n      <li>Stapenor (AT);</li>\n      <li>Syntarpen (PL);</li>\n      <li>Wydox (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26373317\"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26229122\"></a>Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dahlgren A. Adverse drug reactions in home care patients receiving nafcillin or oxacillin. <i>Am J Health-Syst Pharm</i>. 1997;54(10):1176-1179.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/9161625/pubmed\" target=\"_blank\" id=\"9161625\">9161625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Faden D, Faden HS. The high rate of adverse drug events in children receiving prolonged outpatient parenteral antibiotic therapy for osteomyelitis. <i>Pediatr Inf Dis J</i>. 2009;28(6):539-541.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/19483522/pubmed\" target=\"_blank\" id=\"19483522\">19483522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maraqa NF, Gomez MM, Rathore HH, et al. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. <i>Clin Inf Dis</i>. 2002;34(1):50-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/11731945/pubmed\" target=\"_blank\" id=\"11731945\">11731945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Disease Society of America. <i>Clin Infect Dis</i>. 2009;49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olans RN and Weiner LB, &ldquo;Reversible Oxacillin Hepatotoxicity,&rdquo; <i>J Pediatr</i>, 1976, 89(5):835-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/978335/pubmed\" target=\"_blank\" id=\"978335\">978335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxacillin for Injection [prescribing information]. Princeton, NJ: Sandoz Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxacillin Injection [prescribing information]. Deerfield, IL: Baxter Healthcare; received March 7, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prober CG, Stevenson DK, and Benitz WE, &ldquo;The Use of Antibiotics in Neonates Weighing Less Than 1200 Grams,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(2):111-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/2179837/pubmed\" target=\"_blank\" id=\"2179837\">2179837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15494903\"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright AJ, &ldquo;The Penicillins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/10090000/pubmed\" target=\"_blank\" id=\"10090000\">10090000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo; <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxacillin-drug-information/abstract-text/2254575/pubmed\" target=\"_blank\" id=\"2254575\">2254575</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9724 Version 138.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20452679\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F204217\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F204193\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F204208\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F204194\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F204195\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20548161\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204167\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F204151\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F204171\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F204170\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F26191114\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204158\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204174\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204155\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299797\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204160\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204176\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F204177\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F204178\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F204165\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204154\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F204173\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323563\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038712\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9724|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxacillin-patient-drug-information\" class=\"drug drug_patient\">Oxacillin: Patient drug information</a></li><li><a href=\"topic.htm?path=oxacillin-pediatric-drug-information\" class=\"drug drug_pediatric\">Oxacillin: Pediatric drug information</a></li></ul></div></div>","javascript":null}